Psyence Biomedical Ltd.
PBM
$0.73
-$0.03-3.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.67M | 3.41M | 3.37M | 3.11M | 2.85M |
| Depreciation & Amortization | 5.00K | 4.70K | 4.30K | 3.20K | 2.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.45M | 4.10M | 3.85M | 3.63M | 3.41M |
| Operating Income | -4.45M | -4.10M | -3.85M | -3.63M | -3.41M |
| Income Before Tax | -3.70M | -2.80M | -327.00K | -24.13M | -47.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.70 | -2.80 | -0.33 | -24.13 | -47.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.70M | -2.80M | -327.00K | -24.13M | -47.93M |
| EBIT | -4.45M | -4.10M | -3.85M | -3.63M | -3.41M |
| EBITDA | -4.44M | -4.09M | -3.85M | -3.63M | -3.41M |
| EPS Basic | -43.16 | -39.98 | -34.11 | -17.05 | -- |
| Normalized Basic EPS | -25.88 | -21.94 | -17.48 | -8.74 | -- |
| EPS Diluted | -43.17 | -39.98 | -34.11 | -17.05 | -- |
| Normalized Diluted EPS | -25.88 | -21.94 | -17.48 | -8.74 | -- |
| Average Basic Shares Outstanding | 520.70K | 283.70K | 114.20K | 57.10K | -- |
| Average Diluted Shares Outstanding | 520.70K | 283.70K | 114.20K | 57.10K | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |